FindTrial
Sign In

to compare palonosetron and ondansetron in preventing postoperative nausea and vomiting in patients undergoing renal transplant.

To compare the effect of palonosetron and ondansetron in preventing post operative nausea vomiting in patient undergoing living donor renal transplantation : a randomized double blind observational study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/09/021417
Enrollment
112
Registered
2019-09-25
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N186- End stage renal disease

Interventions

Control Intervention1: Palonosetron: 5-HT3 receptor antagonist used to prevent postoperative nausea and vomiting with a longer half life of 40-50 hrs . Prevents both early and late onset post operativ

Sponsors

NIL
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Renal transplant recipients

Exclusion criteria

Exclusion criteria: History of motion sickness History of chronic anti emetic medications Known smokers History of allergy to ondensetron and polonosetron

Design outcomes

Primary

MeasureTime frame
To compare the effects of polonosetron and ondensteronin preventing post operative nausea and vomiting using PONV score wengritzky Rt.alTimepoint: To compare the effects of polonosetron and ondensteronin preventing post operative nausea and vomiting using PONV score wengritzky Rt.al at 0,1hr, 6hr, 12hr,24hr and 72 hrs after surgery—

Secondary

MeasureTime frame
Not applicableTimepoint: Not applicable—

Countries

India

Contacts

Public ContactTanvi bhargava

Sanjay Gandhi post graduate institute of medical sciences

tanvib06@gmail.com07080995711

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026